An intervention can change body composition without improving the abilities people want to preserve. This randomized trial measured both. Primary report
Study snapshot
The double-blind study enrolled 52 healthy older men with low baseline IGF-1 and well-preserved function. After six months, growth hormone increased lean mass and reduced fat mass relative to placebo, without significant strength or endurance improvement. One cognitive test favored treatment, while others did not. Side effects were more frequent, and 26% of hormone recipients required dose reduction. Primary report
Our appraisal: neither an all-positive nor an all-negative summary works
Calling the trial a success solely because lean mass changed would ignore the functional objective. Calling every endpoint negative would erase the isolated cognitive result. A faithful appraisal retains the mixed pattern while asking which outcomes were primary and how multiple comparisons were handled.
Low IGF-1 in this selected population should not be casually relabeled as a diagnosis of pituitary disease. The clinical setting and enrollment criteria matter when deciding which other patients the results might inform.
Safety deserves equal prominence. Counting incidents is not the same as counting people affected: one person may experience several events. A full harms table should preserve both denominators where available, alongside severity, withdrawals, and treatment adjustments.
The absence of a demonstrated functional gain also changes the interpretation of tolerability. A burden of side effects must be considered against the benefits actually observed, not against hoped-for anti-aging outcomes. The report does not establish improved independence or provide a treatment recommendation for healthy aging.
Frequently asked questions
Was the study placebo controlled?
Yes, with a double-blind design.
Did improved lean mass translate into better tested physical function?
The reported strength and endurance comparisons did not demonstrate that.
Were all cognitive tests favorable?
No. The pattern was mixed.
Were treatment adjustments necessary?
Dose reduction was reported among hormone recipients.
Are adverse-event incidents the same as affected participants?
No. Repeated events can occur in one participant.
Does low IGF-1 alone define the study as pituitary-disease treatment?
No. Preserve the actual enrollment description.
What is the central evidence boundary?
Body-composition change is not established functional rejuvenation.